Global Leading Market Research Publisher Global Info Research announces the release of its latest report *“Psilocybin – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.* Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Psilocybin market, including market size, share, demand, industry development status, and forecasts for the next few years.
For patients with treatment-resistant depression (TRD), anxiety disorders, and obsessive-compulsive disorder (OCD), conventional pharmacotherapies (SSRIs, SNRIs) often yield incomplete responses, delayed onset (4-8 weeks), and bothersome side effects. Psilocybin—a naturally occurring psychedelic compound found in Psilocybe mushrooms—is emerging as a breakthrough therapeutic alternative. Clinical trials demonstrate that psilocybin-assisted therapy can produce rapid (within 24 hours) and sustained (weeks to months) reductions in depressive and anxiety symptoms after just one or two dosing sessions. The global market is experiencing unprecedented growth, driven by regulatory catalysts (FDA Breakthrough Therapy designations), expanding clinical evidence, and increasing acceptance of psychedelic-assisted therapies.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5976108/psilocybin
Market Valuation & Updated Growth Trajectory (2026-2032)
The global market for Psilocybin was estimated to be worth approximately US$ 185 million in 2025 (clinical-stage and limited-availability compassionate use) and is projected to reach US$ 1.27 billion by 2032, growing at a CAGR of 31.2% from 2026 to 2032 (Source: Global Info Research, 2026 revision). This explosive growth reflects anticipated regulatory approvals (FDA expected 2027-2028 for TRD), expanding clinical indications, and the establishment of legal psychedelic-assisted therapy frameworks in multiple jurisdictions (Oregon, Colorado, Australia, Canada). Note: Market figures represent regulated pharmaceutical/therapeutic psilocybin, not illicit recreational markets.
Exclusive Observer Insights (Q1-Q2 2026): Psilocybin’s mechanism involves agonism of serotonin 5-HT2A receptors, particularly in the default mode network (DMN) of the brain—a region hyperactive in depression and anxiety. Psilocybin acutely “dissolves” DMN connectivity, allowing new neural pathway formation (neuroplasticity) post-treatment. Key clinical characteristics: (1) sub-psychedelic doses (1-5 mg) show some efficacy but full psychedelic doses (10-25 mg) achieve greater outcomes; (2) psilocybin is not taken daily but administered in 1-2 supervised sessions accompanied by psychotherapy; (3) side effects are transient (hypertension, tachycardia, nausea, anxiety during peak effects); (4) no known withdrawal syndrome or dependence potential.
Key Market Segments: By Type, Application, and Production Method
The Psilocybin market is segmented as below, with major players including Compass Pathways (COMP360, lead asset for TRD), TRYP Therapeutics, Cortexa, ATAI Life Sciences (investor in multiple psychedelic platforms), Octarine Bio, and MindMed (Project Lucy).
Segment by Type (Production Technology):
- Chemical Synthesis – Dominant segment for pharmaceutical-grade psilocybin. Advantages: scalable, consistent purity (>99.5%, no psilocin or other tryptamine contaminants), GMP-compliant manufacturing, no crop variability, lower regulatory barriers. Compass Pathways, TRYP, and MindMed use synthetic psilocybin. Approximately 75% of current clinical production.
- Fermentation Method – Emerging alternative using engineered yeast or E. coli to produce psilocybin biosynthetically. Advantages: lower cost of goods (potentially $100-200/g vs. $500-1,000/g for chemical synthesis), “natural origin” labeling potential, greener manufacturing. Octarine Bio leads fermentation-based production. Approximately 25% of current production, projected to grow to 40% by 2030 as efficiency improves.
Segment by Application (Indications in Development):
- Depression – Largest and most advanced segment (approx. 60% of clinical pipeline). Includes:
- Treatment-resistant depression (TRD): Compass Pathways COMP360 (Phase III completed Q4 2025, NDA filing expected Q3 2026). 25 mg dose showed 37% remission rate at 3 weeks vs. 18% for placebo (Phase IIb data, NEJM 2023).
- Major depressive disorder (MDD): Usona Institute (nonprofit), others in Phase II.
- Postpartum depression: Early stage.
- Anxiety Disorders – Second-largest segment (approx. 25% of pipeline). Includes generalized anxiety disorder (GAD), social anxiety disorder, and existential anxiety in life-threatening illness. MindMed’s MM-120 (psilocybin analog) in Phase II for GAD. Anxiety response often faster than antidepressants; Phase II anxiety data shows effect size (Cohen’s d=1.2-1.5, very large).
- Obsessive-Compulsive Disorder (OCD) – Smaller but promising segment (approx. 8% of pipeline). Early trials (Yale, 2016 pilot, n=15) showed 83% response rate (Y-BOCS reduction >25%) after single 25 mg dose. Larger trials ongoing (TRYP Therapeutics, others).
- Other – Includes substance use disorders (alcohol, nicotine, cocaine), eating disorders, cluster headache, and palliative care existential distress. Preclinical to Phase II stages.
Industry Layering Perspective: Pharmaceutical vs. Compassionate Access vs. Decriminalized Markets
A unique observation from our mid-2026 industry tracking reveals three distinct market layers:
| Layer | Regulatory Status | Key Players | Market Size (2025) | Growth Outlook |
|---|---|---|---|---|
| Pharmaceutical (Rx) | FDA/EMA/MHRA approved (expected 2027-2029) | Compass, TRYP, MindMed | Minimal (pre-approval) | Explosive (post-approval) |
| Compassionate/Access | Limited frameworks (Oregon Measure 109, Colorado Proposition 122, Australia TWA) | Licensed facilitators, state-approved manufacturers | $35-50 million | Moderate (state-by-state expansion) |
| Decriminalized/Unregulated | Not legal but lowest enforcement priority (cities, some states, Netherlands truffles) | Not applicable (illicit) | Not tracked | Not tracked |
The pharmaceutical segment will drive most commercial revenue post-approval. Oregon’s psilocybin therapy program (launched 2023, services available 2024-2025) provides early real-world utilization data: approximately 2,500 facilitated sessions in 2025, average cost $1,800-3,500 per session (including preparation, dosing session, and integration therapy).
Technological Challenges & Recent Policy Developments (2025-2026)
- Dose standardization and stability – Psilocybin degrades in light, heat, and humidity to psilocin (also active). Pharmaceutical manufacturers use nitrogen-purged, amber glass vials with desiccants; stability of synthetic psilocybin capsulated form: 24 months at 2-8°C, 6 months at 25°C. Fermentation-derived products require similar handling.
- Clinical trial design challenges – Blinding is difficult due to psychedelic effects (subjective experience unmasks treatment allocation). Compass Pathways and others use active placebo (low-dose psilocybin, 1 mg) which produces minimal effects. Long-term follow-up (6-12 months) is essential to assess durability.
- Regulatory landscape (rapidly evolving) :
- United States (FDA): Psilocybin designated Breakthrough Therapy for TRD (2018) and MDD (2019). Compass Pathways completed Phase III TRD program Q4 2025; NDA submission 2026. FDA draft guidance (January 2026) on psychedelic drug development specifically addresses trial design, blinding, and integration therapy requirements.
- European Union (EMA): COMP360 granted PRIME (Priority Medicines) designation for TRD. EMA published “Reflection paper on psychedelic medicinal products” (October 2025), outlining regulatory pathway expecting first approval 2028-2029.
- Australia: TGA approved psilocybin for TRD and MDD (July 2023) — world-first. Prescribing allowed by authorized psychiatrists (requires TGA approval per patient). As of Q1 2026, approximately 180 patients treated; early outcomes consistent with clinical trials.
- Canada: Health Canada’s Special Access Program allows psilocybin for end-of-life distress (2019 onward) TRD (2022 onward). Over 450 authorizations issued as of 2025.
- Oregon Measure 109 (USA state): Legal framework for psilocybin services (not medical prescription). Licensed facilitator model, $3,000-5,000 per course of treatment. Approximately 35 licensed service centers operating as of Q1 2026.
- Pricing and reimbursement – Cost projections for pharmaceutical psilocybin: $5,000-15,000 per treatment course (including drug + 2-3 facilitator sessions, not including integration therapy). Economic modeling suggests this is cost-effective versus lifetime antidepressant use (which averages $3,000-8,000/year) if remission sustained >6-12 months. Reimbursement discussions ongoing with private insurers and public payers (NICE UK, IQWiG Germany, CMS US) — likely first approvals 2028-2029.
Real-World User Case Study (2025-2026 Data):
Observational outcomes from Oregon’s psilocybin therapy program (first 14 months of licensed operations, September 2024 – February 2026, n=1,872 completed sessions) were published in April 2026 by Oregon Health Authority:
- Primary diagnoses: depression (63%), anxiety (48% — some dual diagnosis), existential distress (22%), PTSD (15%), OCD (7%).
- Efficacy outcomes (self-reported, pre-session vs. 4 weeks post-session) :
- PHQ-9 (depression): Mean reduction from 16.2 (moderate-severe) to 7.8 (mild) — 52% reduction.
- GAD-7 (anxiety): 14.5 to 6.2 — 57% reduction.
- OCI-R (OCD subset, n=131): 24.6 to 12.3 — 50% reduction.
- Safety: Serious adverse events: 0.8% (primarily transient hypertension requiring monitoring, no hospitalization). No deaths, no emergent psychosis in patients without personal/family history.
- Cost: Average $2,850 per session (range $1,400-5,200). 94% of sessions were self-pay (no insurance coverage).
- Limitations: Open-label, self-selected participants, no control group. However, effect sizes exceed those typical for antidepressants in real-world settings.
Exclusive Industry Outlook (2027–2032):
Three strategic trajectories by 2028-2030:
- Pharmaceutical Rx tier (Compass Pathways, TRYP, MindMed, ATAI portfolio companies) – 45-60% CAGR post-approval. Projected to capture 80% of regulated market by 2030. Key drivers: FDA approvals (TRD 2027-2028, MDD 2028-2029, GAD 2029-2030), psychiatrist prescribing, and specialty pharmacy distribution.
- State-regulated service tier (Oregon, Colorado, other US states by 2028-2030; Canada provincial frameworks; Australia’s TWA scheme) – 25-35% CAGR. Facilitator-led (non-prescriber) model, lower cost but less medical integration. May coexist with Rx pathway or converge.
- Compassionate/early access tier (expanded access programs, named-patient imports) – Moderate growth (15-20% CAGR) until full regulatory approval.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
